Home › NCT06701214

The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository

Discovering Outcomes in Clonal Hematopoiesis: The Clonal Hematopoiesis and Inflammation in VasculaturE (CHIVE) Registry and Biorepository

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patient greater than or equal to 18 years old at time of consent
* Able to provide informed consent
* Idiopathic cytopenia (ICUS) or idiopathic cytoses (elevated blood counts without disease or explanation); clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP) or individuals at higher risk for clonal hematopoiesis (ex. patients with known diagnosis of solid tumors or cardiovascular disease)

Exclusion Criteria:

* Unable to provide consent
* Diagnosis of active hematologic malignancy. For example, a diagnosis of CMML, AML, MDS, MPN; History of hematologic malignancy is NOT exclusionary if in complete remission (e.g. previous myeloma or lymphoma)

About the study

This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as well as increased risk of heart disease.

What is being tested

• Blood collection (other)
• Saliva collection (other)
• Bone marrow collection (other)

Sponsor: Vanderbilt-Ingram Cancer Center · Participants: 800 · Started: Oct 28, 2020

Contact the study team

• Vanderbilt-Ingram Services for Timely Access · Phone: 800-811-8480

Official record on ClinicalTrials.gov — NCT06701214

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.